{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.52","value":"3"},{"groupId":"OG001","spread":"0.47","value":"1"},{"groupId":"OG002","spread":"0.52","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Response rate was defined as a 50% reduction in the Hamilton Depression Rating Scale (HAM-D) scores over 4 weeks. The HAM-D can have total scores that range from 0 to 50, with higher scores indicating greater depression. Scores over 14 are considered to be in the depressed range.","groups":[{"description":"Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and placebo oncedaily by mouth for the second 4 weeks","id":"OG000","title":"Placebo-Placebo"},{"description":"Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and escitalopram 10 mg once daily by mouth for the second 4 weeks","id":"OG001","title":"Placebo-Escitalopram"},{"description":"Participants in this arm were randomzied to receive escitalopram f10 mg once daily by mouth or the first 4 weeks and placebo once daily by mouth for the second 4 weeks","id":"OG002","title":"Escitalopram-Placebo"}],"paramType":"NUMBER","populationDescription":"The efficacy analysis was intent to treat and all randomized participants were analyzed","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Depression Response Rate of Escitalopram Oxalate 10 mg Once Daily Compared to Placebo Once Daily for Major Depressive Disorder","type":"PRIMARY","unitOfMeasure":"number of participants with response"}